COMMUNIQUÉS West-GlobeNewswire

Glass House Brands to Host Fourth Quarter and Full Year 2025 Earnings Call on March 24, 2026
19/03/2026
LONG BEACH, Calif. and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Backpage Sex Trafficking Survivors Break Silence, Demand Investigation of Uncharged Enablers as Compensation Deadline Approaches
19/03/2026
WASHINGTON, March 19, 2026 (GLOBE NEWSWIRE) -- With a March 31st court-imposed deadline approaching for Backpage sex trafficking victims to seek financial compensation, a group of approximately 20 survivors is publicly [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
SK pharmteco réaffirme sa stratégie à trois unités d’activité et renforce son pôle mondial de thérapie génique grâce à un engagement de financement
19/03/2026
RANCHO CORDOVA, Californie, 19 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé aujourd’hui un engagement de financement significatif visant à soutenir des initiatives stratégiques au sein de son activité de [...]
Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
19/03/2026
SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong [...]
The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function
19/03/2026
The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the [...]
NMDP Celebrates Bipartisan Senate Introduction of Life-saving Blood Stem Cell Therapeutic and Research Reauthorization Act
19/03/2026
The C.W. Bill Young Cell Transplantation Program Has Impacted Nearly 150,000 Lives Since Inception, a 33% Increase in the Last Five Years MINNEAPOLIS, March 19, 2026 (GLOBE NEWSWIRE) -- NMDP SM , the nonprofit [...]
New partnership to fast-track Canadian health technology from innovation to patient care
19/03/2026
AIM Institute and CAN Health Network join forces to help Canadian solutions reach clinicians and patients faster NEW WESTMINSTER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Royal Columbian Hospital Foundation’ [...]
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
19/03/2026
Wegovy ® HD demonstrated a mean weight loss of 20.7% 1 , and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial First US FDA approval of a GLP-1 treatment under the Commissioner’s [...]
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
19/03/2026
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 [...]
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
19/03/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to [...]
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
19/03/2026
- Purchase commitment is for a minimum of $1.475 million of Symvess product - DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing [...]
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
19/03/2026
NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S [...]
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
19/03/2026
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX [...]
Causeway Therapeutics Presents Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis at RNA Leaders Europe 2026
19/03/2026
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced [...]
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
19/03/2026
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS-driven tumors [...]
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client
19/03/2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
19/03/2026
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
19/03/2026
BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited [...]

Pages